Most Read Articles
Dr. Joseph Delano Fule Robles, 6 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
5 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.

Anti-PD-1 combination therapy the way forward

Dr Joslyn Ngu
30 Oct 2017
L-R: Prof Keith Kerr, Prof Tasuku Honjo and Prof Ming Tsao.

Combination therapy for programmed death-1 (PD-1) blockade using mitochondrial activators, especially peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α), may be the next focus of cancer research, says an expert.

Just like the role of penicillin in starting the era of antibiotics, the discovery of PD-1 is the starting point for immunotherapy in cancer. This is just the beginning and there will be more discovery to come, said Professor Tasuku Honjo, of the Department of Immunology and Genomic Medicine, Kyoto University Graduate School of Medicine, Japan. Honjo is the first scientist to identify and clone PD-1.

PD-1 is a checkpoint protein on T-cells that functions as an ‘off switch’ to stop the cells from attacking other cells in the body. It is only able to function if it is attached to programmed death-ligand 1 (PD-L1). In some cancers, the cancer cells have substantial amounts of PD-L1 to help them evade immune attack. Immunotherapy drugs can target either PD-1 or PD-L1 and increase the immune response against cancer cells. [Annu Rev Immunol 2008;26:677–704]

Immunotherapy using PD-1 blockade has improved the outcomes for cancer patients. However, more research is necessary to improve the efficacy in patients who are less sensitive to the treatment. Currently, there are numerous on-going studies on immunotherapy-based combination therapy for cancer. This is because there are endless possibilities for combination therapy involving immune checkpoint inhibitors, said Honjo. Possible combinations would include combining with currently established treatments, low dose anti-cancer drugs or low dose irradiation. There are also the possibilities of combination with blockade of other negative regulators such as LAG3 and TIM3, and combination with mitochondrial activators, he continued.

Mitochondrial activators are an especially viable candidate for combination therapy with anti-PD-1 drugs, said Honjo. They are also good markers to assess the effectiveness of immunotherapy. Tumour reactive cytotoxic T-cells in draining lymph nodes (DLN) have been shown to have elevated mitochondrial mass and more reactive oxygen species (ROS). The formation of ROS synergized the tumoricidal activity of PD-1 blockade by expansion of cytotoxic T-cells in both the DLN and tumor.

These T-cells carry the activation of mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK) and other transcription factors such as PGC-1α and T-bet, he said. Alone, the direct activators of mTOR, AMPK, or PGC-1α do not have any effects on tumor growth. However, when used in combination with PD-1 blockade therapy, they had a synergistic effect. As such, Honjo believes this will pave the way for the development of new combinatorial therapies with anti-PD-1.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 6 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
5 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.